
Ardelyx (ARDX) Stock Forecast & Price Target
Ardelyx (ARDX) Analyst Ratings
Bulls say
Ardelyx is a promising biopharmaceutical company that has developed a platform for discovering new biological mechanisms and pathways to develop innovative therapies with few side effects. The recent market volatility for its two FDA-approved products, Ibsrela and Xphozah, created an entry point for its stock, as Ardelyx maintains an excellent chance of success in the treatment space. The company has a strong pipeline and has established key partnerships with specialty pharmacies, increasing the likelihood of successful commercialization.
Bears say
Ardelyx is facing reimbursement headwinds and challenges in fulfilling times for their product Ibsrela due to timing and the departure of their Chief Commercial Officer. Additionally, the company's expansion into the treatment of Chronic Idiopathic Constipation (CIC) may not be enough to offset potential setbacks and low patient satisfaction with current treatment options.
This aggregate rating is based on analysts' research of Ardelyx and is not a guaranteed prediction by Public.com or investment advice.
Ardelyx (ARDX) Analyst Forecast & Price Prediction
Start investing in Ardelyx (ARDX)
Order type
Buy in
Order amount
Est. shares
0 shares